I’ve looked at MZT (formerly NMPS) and EXAS from time to time, but I haven’t been too impressed with either.
Cancer diagnostics have to be really good to be useful for testing a general population. Otherwise, the number of false positives will overwhelm the number of cancers detected.
P.S. Being physically close to a company is not a good enough reason to invest. Pro-Pharmaceuticals is practically next door, but I’m glad I didn’t bite (#msg-2596707).
Market Data 
Markets 
AI
